FMC Corporation reports news on its global agricultural sciences business, including crop protection solutions, biologicals, crop nutrition, digital and precision agriculture, and research into herbicide, insecticide and fungicide active ingredients. Company updates commonly cover quarterly results, outlook commentary, dividend declarations, executive conference appearances, and regulatory approvals for products such as Isoflex® active.
FMC news also reflects the operating issues of a crop protection supplier, including regional revenue trends, product commercialization, operational priorities, capital-structure matters, and governance developments affecting its board and incentive plans.
FMC (NYSE:FMC) announced that chairman, CEO and president Pierre Brondeau and executive vice president and CFO Andrew Sandifer will speak at the BMO Global Farm to Market Chemicals Conference on May 14, 2026, at 1:15 p.m. Eastern Time. A live webcast will be available on FMC's investor website.
FMC (NYSE:FMC) signed a definitive agreement to sell FMC India Private Limited to Crystal Crop Protection Limited for $252 million USD, subject to customary adjustments for cash, debt and working capital.
The transaction is expected to close by year-end 2026 pending regulatory approvals. FMC will receive cash from ongoing India operations until closing and will allocate all proceeds to debt reduction. Crystal acquires India commercial operations, a license to FMC brands in India, and preferred supply and pipeline access; FMC will continue R&D and global manufacturing activities in India.
FMC (NYSE:FMC) reported Q1 2026 revenue of $759M (down 4% vs. Q1 2025) and adjusted EBITDA of $72M. GAAP net loss was $281M and GAAP loss per diluted share was $2.25; adjusted loss per share was $0.23. Sales excluding India were $762M. The company reaffirmed full‑year 2026 guidance: revenue excl. India of $3.60B–$3.80B, adjusted EBITDA of $670M–$730M, adjusted EPS of $1.63–$1.89, and free cash flow of -$65M to $65M. Board‑authorized strategic alternatives review is ongoing.
FMC (NYSE: FMC) declared a regular quarterly dividend of $0.08 per share, payable July 16, 2026, to shareholders of record at the close of business June 30, 2026.
This is a routine cash distribution; no changes to dividend policy or supplemental financial details were announced.
FMC (NYSE: FMC) announced EU regulatory approval for Isoflex® active (bixlozone) on April 6, 2026. The approval enables filing of formulated products for cereals, corn, oilseed rape and potato covering more than 55 million planted hectares in the EU, with product launches anticipated beginning in 2027.
Isoflex® active is HRAC Group 13 and offers a new mode of action to manage resistant grass and broadleaf weeds; global registrations exist in multiple countries and R&D continues for additional crops.
FMC (NYSE: FMC) will release first quarter 2026 earnings on Wednesday, April 29, 2026 after market close and will host a public webcast conference call on Thursday, April 30, 2026 at 9:00 a.m. ET.
According to the company, the release will be posted on its investor website and a live webcast and dial-in details are provided for investors and analysts.
FMC Corporation (NYSE: FMC) announced that Chairman and CEO Pierre Brondeau and EVP & CFO Andrew Sandifer will speak at the J.P. Morgan Industrials Conference on March 18, 2026 at 10:05 a.m. ET. A live webcast will be available at www.fmc.com/investors.
FMC (NYSE: FMC) declared a regular quarterly dividend of $0.08 per share, payable on April 16, 2026 to shareholders of record at the close of business on March 31, 2026.
This distribution signals a current cash return to shareholders via the company's quarterly dividend program.
FMC (NYSE: FMC) announced the election of Michael F. Barry to its Board of Directors, effective February 27, 2026. He will join the Audit and Compensation and Human Capital committees and brings 30+ years in specialty chemicals and prior CEO and chairman experience.
Barry led Quaker Houghton through major growth, including revenue expansion from $451 million in 2009 to $1.8 billion in 2021 and 27 strategic acquisitions, and will advise on FMC's 2026 strategic priorities.
FMC (NYSE: FMC) announced that HRAC has classified rimisoxafen as the industry's first dual mode of action herbicide, designated under HRAC Groups 12 and 32. The classification recognizes dual inhibition of PDS and SDPS, increasing the barrier to weed resistance.
Rimisoxafen targets palmer amaranth and waterhemp, is intended for broadacre crops, was discovered at FMC's Stine Research Center, and regulatory dossiers will begin in 2026.